Actively Recruiting
Evaluation of Blood Protein O-GlcNAcylation Levels in Children
Led by Nantes University Hospital · Updated on 2025-02-13
240
Participants Needed
1
Research Sites
574 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Stimulation of O-GlcNAcylation has been shown to be beneficial in several acute pathologies and different animal models, such as haemorrhagic and septic shock, and ischaemia-reperfusion (cerebral and cardiac). It could therefore be interesting to use this approach in children in order to limit the impact of various pathologies inducing SIRS, such as extracorporeal circulation for major surgery, septic shock or various traumas. The investigators demonstrated in 2 different animal models (endotoxemia by injection of Lipopolysaccharides and caecal puncture ligation model) with 3 different pharmacological molecules (Glucosamine, ThiametG and NButGT) that stimulation of O-GlcNAcylation was beneficial in the early phase of septic shock with a marked effect on cardiac function and survival. The investigators thus demonstrated that stimulation of O-GlcNAcylation was beneficial in young rats in septic shock. However, none of this work has yet been reproduced in humans, either children or adults.
CONDITIONS
Official Title
Evaluation of Blood Protein O-GlcNAcylation Levels in Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age from 0 to 17 years at the time of sampling, including premature infants
- Children visiting the hospital for blood sampling as part of a pre-operative check-up, allergy check-up, or other non-sepsis-related pathology
- Premature infants monitored with blood samples for prematurity management
- Collection of umbilical cord blood
- Signed consent from parents or guardians
- Children with suspected or diagnosed sepsis according to the 2016 definition
- Signed bio-collection consent for septic group
You will not qualify if you...
- Children with an infection or fever (for healthy group)
- Children with immune deficiency
- Children with autoimmune disease
- Children with metabolic disease
- Children with hematological diseases
- Children with genetic diseases
- Unsigned consent or bio-collection consent
- Refusal to participate by parents or child
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nantes University Hospital
Nantes, France, 44093
Actively Recruiting
Research Team
M
Manon Denis, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here